TCGA-XF-A8HD-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 97.37187911
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.720
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.480
- IL6_JAK_STAT3_SIGNALING+0.420
- E2F_TARGETS+0.350
- INFLAMMATORY_RESPONSE+0.310
- PROTEIN_SECRETION+0.310
- TGF_BETA_SIGNALING+0.310
- COMPLEMENT+0.300
- APOPTOSIS+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- OXIDATIVE_PHOSPHORYLATION-0.260
- PANCREAS_BETA_CELLS-0.240
- WNT_BETA_CATENIN_SIGNALING-0.220
- ADIPOGENESIS-0.170
- APICAL_SURFACE-0.160
- CHOLESTEROL_HOMEOSTASIS-0.140
- ANDROGEN_RESPONSE-0.130
- KRAS_SIGNALING_DN-0.130
- HEDGEHOG_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG745 | — | — | 0.849 |
| 2 | SRR8942957 | — | — | 0.843 |
| 3 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.823 |
| 4 | TCGA-BH-A0BW-01A-11R-A115-07 | — | D | 0.811 |
| 5 | SRR5088852 | — | — | 0.808 |
| 6 | TCGA-55-8089-01A-11R-2241-07 | — | cohortA1 | 0.807 |
| 7 | ea0e56e4-d9e3-44a2-9bdb-2e98554f6bff | — | — | 0.804 |
| 8 | SRR8392882 | — | cohortA1 | 0.803 |
| 9 | C3L-00904 | — | cohortSQ1 | 0.794 |
| 10 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.720 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |